Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) released its earnings results on Thursday. The biotechnology company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16), Zacks reports. Novozymes A/S had a return on equity of 6.52% and a net margin of 14.22%.
Novozymes A/S Stock Performance
Shares of NVZMY stock opened at $69.51 on Thursday. The stock has a market cap of $28.82 billion, a PE ratio of 46.97, a price-to-earnings-growth ratio of 3.00 and a beta of 0.92. The stock has a 50-day moving average of $63.48 and a 200-day moving average of $60.52. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.67 and a quick ratio of 1.03. Novozymes A/S has a one year low of $49.90 and a one year high of $75.27.
Wall Street Analyst Weigh In
NVZMY has been the subject of several recent research reports. Zacks Research raised Novozymes A/S from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Kepler Capital Markets upgraded shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy”.
Novozymes A/S Company Profile
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).
See Also
- Five stocks we like better than Novozymes A/S
- Analog Devices’ AI Pivot Could Push Shares to Fresh Highs
- One Platform, Every Ailment: Hinge Health’s Gamble
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
